Literature DB >> 18209877

Cushing's syndrome: aftermath of the cure.

Rosario Pivonello1, Maria Cristina De Martino, Monica De Leo, Libuse Tauchmanovà, Antongiulio Faggiano, Gaetano Lombardi, Annamaria Colao.   

Abstract

Cushing's syndrome (CS) is a chronic and systemic disease caused by endogenous or exogenous hypercortisolism, associated with an increase of mortality rate due to the clinical consequences of glucocorticoid excess, especially cardiovascular diseases. After cure, usually obtained by the surgical removal of the tumor responsible for the disease, the normalization of cortisol secretion is not constantly followed by the recovery of the clinical complications developed during the active disease, and it is often followed by the development of novel clinical manifestations induced by the fall of cortisol levels. These evidences were mostly documented in patients with pituitary-dependent CS, after surgical resection of the pituitary tumor. Indeed, despite an improvement of the mortality rate, metabolic syndrome and the consequent cardiovascular risk have been found to partially persist after disease remission, strictly correlated to the insulin resistance. Skeletal diseases, mainly osteoporosis, improve after normalization of cortisol levels but require a long period of time or the use of specific treatment, mainly bisphosphonates, to reach the normalization of bone mass. A relevant improvement or resolution of mental disturbances has been described in patients cured from CS, although in several cases, cognitive decline persisted and psychological or psychiatric improvement was erratic, delayed, or incomplete. On the other hand, development or exacerbation of autoimmune disorders, mainly thyroid autoimmune diseases, was documented in predisposed patients with CS after disease remission. The totality of these complications persisting or occurring after successful treatment contribute to the impairment of quality of life registered in patients with CS after disease cure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18209877     DOI: 10.1590/s0004-27302007000800025

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN: 0004-2730


  17 in total

1.  Classification and surgical treatment for 180 cases of adrenocortical hyperplastic disease.

Authors:  Yushi Zhang; Hanzhong Li
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Primary adrenal hypercortisolism: minimally invasive surgical treatment or medical therapy? A retrospective study with long-term follow-up evaluation.

Authors:  Mario Guerrieri; Roberto Campagnacci; Andrea Patrizi; Chiara Romiti; Giorgio Arnaldi; Marco Boscaro
Journal:  Surg Endosc       Date:  2010-03-25       Impact factor: 4.584

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 4.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

5.  Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?

Authors:  A Scillitani; G Mazziotti; C Di Somma; S Moretti; A Stigliano; R Pivonello; A Giustina; A Colao
Journal:  Osteoporos Int       Date:  2013-12-06       Impact factor: 4.507

6.  Coping strategies have a strong impact on quality of life, depression, and embitterment in patients with Cushing's disease.

Authors:  Sonja Siegel; Monika Milian; Bernadette Kleist; Tsambika Psaras; Maria Tsiogka; Dagmar Führer; Maria Koltowska-Häggström; Jürgen Honegger; Oliver Müller; Ulrich Sure; Christa Menzel; Michael Buchfelder; Ilonka Kreitschmann-Andermahr
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

Review 7.  Cushing's disease: the burden of illness.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Chiara Simeoli; Annamaria Colao
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

8.  Death in pediatric Cushing syndrome is uncommon but still occurs.

Authors:  Alexandra Gkourogianni; Maya B Lodish; Mihail Zilbermint; Charalampos Lyssikatos; Elena Belyavskaya; Margaret F Keil; Constantine A Stratakis
Journal:  Eur J Pediatr       Date:  2014-09-23       Impact factor: 3.183

Review 9.  Psychiatric Symptoms in Cushing's Syndrome: A Systematic Review.

Authors:  Tiffany Y Lin; Jasmine Hanna; Waguih William Ishak
Journal:  Innov Clin Neurosci       Date:  2020-01-01

Review 10.  Mifepristone: is there a place in the treatment of Cushing's disease?

Authors:  John D Carmichael; Maria Fleseriu
Journal:  Endocrine       Date:  2012-11-29       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.